A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations

Summary

This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the single-dose pharmacokinetics of FOR-6219 in capsule and tablet formulations in postmenopausal women. The effect of high-fat food on the pharmacokinetics of the tablet formulation will also be evaluated. A total of twelve, post-menopausal women, will be randomised to receive a single oral dose of FOR-6219 in three treatment periods: capsule formulation (fasted); tablet formulation (fed); tablet formulation (fasted)

Timeline

Start

2020-12-10

Primary completion

2021-01-16

Completion

2021-01-16

Drugs

Indications

No indication recorded.